Data from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik(South Texas Accelerated Research Therapeutics), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Muralidhar Beeram(Urology San Antonio), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco), Kyriakos P. Papadopoulos(Texas Oncology), Jeroen Elassaiss‐Schaap(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Drew Rasco(Texas Oncology), Liliana Calderón Delgado, Robert H. Pierce(Mabvax Therapeutics (United States)), Dianna Wu(Memorial Sloan Kettering Cancer Center), S. Peter Kang, Cong Chen(Fujian University of Traditional Chinese Medicine), Xiaoyun Li(Nanjing University), Robert Iannone(Cornell University), Lon Smith(Texas Oncology), Omar Laterza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ronald Drengler(South Texas Accelerated Research Therapeutics), Jill A. Lindia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Guillermo Espino(South Texas Accelerated Research Therapeutics)
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k